Litcius/Paper detail

Histone deacetylase 10, a potential epigenetic target for therapy

Fajuan Cheng, Bin Zheng, Jianwei Wang, Guiting Zhao, Zhongshun Yao, Zhihong Niu, Wei He

2021Bioscience Reports54 citationsDOIOpen Access PDF

Abstract

Histone deacetylase (HDAC) 10, a class II family, has been implicated in various tumors and non-tumor diseases, which makes the discovery of biological functions and novel inhibitors a fundamental endeavor. In cancers, HDAC10 plays crucial roles in regulating various cellular processes through its epigenetic functions or targeting some decisive molecular or signaling pathways. It also has potential clinical utility for targeting tumors and non-tumor diseases, such as renal cell carcinoma, prostate cancer, immunoglobulin A nephropathy (IgAN), intracerebral hemorrhage, human immunodeficiency virus (HIV) infection and schizophrenia. To date, relatively few studies have investigated HDAC10-specific inhibitors. Therefore, it is important to study the biological functions of HDAC10 for the future development of specific HDAC10 inhibitors. In this review, we analyzed the biological functions, mechanisms and inhibitors of HDAC10, which makes HDAC10 an appealing therapeutic target.

Topics & Concepts

HDAC10Histone deacetylaseEpigeneticsHistoneBiologyCancer researchComputational biologyMedicineBioinformaticsGeneticsGeneHistone Deacetylase Inhibitors ResearchProtein Degradation and InhibitorsEpigenetics and DNA Methylation
Histone deacetylase 10, a potential epigenetic target for therapy | Litcius